SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

HEIDENREICH, A. et al. Guía de la EAU sobre el cáncer de próstata: Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado. Actas Urol Esp [online]. 2011, vol.35, n.9, pp.501-514. ISSN 0210-4806.  http://dx.doi.org/10.4321/S0210-48062011000900001.

    1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008; 53:68-80. [ Links ]

    2. US Department of Health and Human Services. Agency for Healthcare Research and Quality Web site. Disponible en: http://www.ahcpr.gov/. [ Links ]

    3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008; 58:71-96. [ Links ]

    4. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe 2008. Eur J Cancer. 2010; 46:765-81. [ Links ]

    5. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002; 168:906-13. [ Links ]

    6. TNM classification of malignant tumors. En: Sobin LH, Gospodariwicz M, Wittekind C, editores. UICC International Union Against Cancer. 7.a ed. Hoboken, NJ: Wiley-Blackwell; 2009. p. 243-8. [ Links ]

    7. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111:58-64. [ Links ]

    8. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control. 2007; 18:279-85. [ Links ]

    9. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360:1310-9. [ Links ]

    10. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360:1320-8. [ Links ]

    11. Van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer. 2010; 46:377-83. [ Links ]

    12. Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H. Problems, objective, and substance of early detection of prostate cancer [en alemán]. Urologe A. 2010; 49:181-9. [ Links ]

    13. Carter HB, Kettermann AE, Ferrucci L, Landis P, Trock BJ, Metter EJ. Prostate specific antigen testing among the elderly; when to stop?. J Urol. 2008; 174(Suppl 1):600. [ Links ]

    14. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol. 1999; 161:835-9. [ Links ]

    15. Loeb S, Catalona WJ. What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels?. Nat Clin Pract Urol. 2009; 6:68-9. [ Links ]

    16. Stephan C, Köpke T, Semjonow A, Lein M, Deger S, Schrader M, et al. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?. Clin Chem Lab Med. 2009; 47:1325-31. [ Links ]

    17. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4,0 ng per millilitre. N Engl J Med. 2004; 350:2239-46. [ Links ]

    18. Kobori Y, Kitagawa Y, Mizokami A, Komatsu K, Namiki M. Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0 ng/ml as a criterion. Int J Clin Oncol. 2008; 13:229-32. [ Links ]

    19. O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009; 27:3591-7. [ Links ]

    20. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009; 27:398-403. [ Links ]

    21. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179:1587-9. [ Links ]

    22. Remzi M, Haese A, Van Poppel H, De La Taille A, Stenzl A, Hennenlotter J, et al. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?. BJU Int. 2010; 106:1138-42. [ Links ]

    23. Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. BJU Int. 2010; 106:1143-7. [ Links ]

    24. Hara R, Jo Y, Fujii T, Kondo N, Yokoyoma T, Miyaji Y, et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology. 2008; 71:191-5. [ Links ]

    25. Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, et al. A prospective randomized comparison of diagnostic efficiency between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008; 11:134-8. [ Links ]

    26. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006; 175:1605-12. [ Links ]

    27. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000; 85:682-5. [ Links ]

    28. Adamakis I, Mitropoulos D, Haritopoulos K, Alamanis C, Stravodimos K, Giannopoulos A. Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream. World J Urol. 2004; 22:281-4. [ Links ]

    29. Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol. 2009; 182:485-90. [ Links ]

    30. Van der Kwast TH, Lopes C, Santonja C, et al. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol. 2003; 56:336-40. [ Links ]

    31. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29:1228-42. [ Links ]

    32. Herkommer K, Kuefer R, Gschwend JE, Hautmann RE, Volkmer BG. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol. 2004; 45:36-41. [ Links ]

    33. Trpkov K, Gao Y, Hay R, Yimaz A. No residual cancer on radical prostatectomy after positive 10-core biopsy: incidence, biopsy findings, and DNA specimen identity analysis. Arch Pathol Lab Med. 2006; 130:811-6. [ Links ]

    34. Fuchsjager M, Shukla-Dave A, Akin Barentsz O, Hricak H. Prostate cancer imaging. Acta Radiol. 2008; 49:107-20. [ Links ]

    35. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisemberg HF. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MRI to the Kattan Nomogram. Radiology. 2007; 242:182-8. [ Links ]

    36. Hoivels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008; 63:387-95. [ Links ]

    37. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35:253-63. [ Links ]

    38. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008; 54:392-401. [ Links ]

    39. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002; 167:1681-6. [ Links ]

    40. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010; 57:551-8. [ Links ]

    41. Beheshti M, Vali R, Langsteger W. [18F]Fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007; 34:1316-7. [ Links ]

    42. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994; 330:242-8. [ Links ]

    43. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280:975-80. [ Links ]

    44. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010; 28:126-31. [ Links ]

    45. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep. 2010; 11:165-71. [ Links ]

    46. Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillan clinical and biochemical characteristics. J Urol. 2010; 184:131-5. [ Links ]

    47. Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer. 2008; 113:286-92. [ Links ]

    48. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010; 28:2810-6. [ Links ]

    49. Studer UE, Whelan P, Albrecht W, Casselman J, De Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006; 24:1868-76. [ Links ]

    50. Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008; 53:941-9. [ Links ]

    51. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352:1977-84. [ Links ]

    52. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008; 100:1144-54. [ Links ]

    53. Heidenreich A, Pfister D, Thüer D, Brehmer B. Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy. BJU Int. 2011;107:220-5. [ Links ]

    54. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int. 2006; 98:788-93. [ Links ]

    55. Yossepowitch O, Eggener SE, Bianco FJ, et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007; 178:493-9. [ Links ]

    56. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005; 95:751-6. [ Links ]

    57. Pierorazio PM, Guzzo TJ, Han M, et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology. 2010; 76:715-21. [ Links ]

    58. Joniau S, Hsu CY, Lerut E, Van Baelen A, Haustermans K, Roskams T, et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol. 2007; 51:388-96. [ Links ]

    59. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol. 2008; 53:253-9. [ Links ]

    60. Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology. 2007; 69:1170-5. [ Links ]

    61. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009; 35:9-17. [ Links ]

    62. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006; CD006019. [ Links ]

    63. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7:472-9. [ Links ]

    64. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006; 97:247-54. [ Links ]

    65. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol. 2009; 27:100-5. [ Links ]

    66. Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet. 2005; 366:572-8. [ Links ]

    67. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009; 27:2924-30. [ Links ]

    68. Swanson GP, Thompson IM, Tangen C, et al. Update of SWOG: 8794 adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Radiat Oncol Biol Phys. 2008; 72:S31. [ Links ]

    69. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181:956-62. [ Links ]

    70. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005; 61:415-9. [ Links ]

    71. Peeters ST, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006; 24:1990-6. [ Links ]

    72. D'Amico A, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer; a randomized controlled trial. JAMA. 2008; 299:289-95. [ Links ]

    73. Bolla M, De Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360:2516-27. [ Links ]

    74. Widmark A, Klepp O, Solberg A, et al, Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373:301-8. [ Links ]

    75. Warde PR, Mason MD, Sydes MR, et al. Intergroup randomized phase III study of androgen deprivation therapy (TPA) plus radiation therapy (RT) in locally advanced prostate cancer (PCa) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). J Clin Oncol. 2010; 28(Suppl):18s. [ Links ]

    76. Mottet N, Peneau M, Mazeron J, Molinie V, Richaud P. Impact of radiotherapy (RT) combined with androgen deprivation (TPA) versus TPA alone for local control in clinically locally advanced prostate cancer. J Clin Oncol. 2010; 28 Suppl:15s. [ Links ]

    77. Ash D, Flynn A, Batterman J, De Reijke T, Lavagnini P, Blank L, ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000; 57:315-21. [ Links ]

    78. Voulgaris S, Nobes JP, Laing RW, Langley SE. State-of-the-art: prostate LDR brachytherapy. Prostate Cancer Prostatic Dis. 2008; 11:237-40. [ Links ]

    79. Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79:1336-42. [ Links ]

    80. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007; 25:5366-73. [ Links ]

    81. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176:1415-9. [ Links ]

    82. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultrahigh dose (86.4Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008; 71:330-7. [ Links ]

    83. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010; 303:1046-53. [ Links ]

    84. Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008; 180:1993-2004. [ Links ]

    85. Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol. 2010; 58:803-15. [ Links ]

    86. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010; 116:323-30. [ Links ]